NCT05119335 - A Study of NKT2152, a HIF2α Inhibitor, in Patients with Advanced Clear Cell Renal Cell Carcinoma | Biotech Hunter

Enrollment

128

Participants

Timeline

Start Date

October 26, 2021

Primary Completion Date

May 31, 2025

Study Completion Date

September 30, 2026

Conditions

CcRCCClear Cell Renal Cell CarcinomaKidney CancerKidney NeoplasmsRenal CancerRenal NeoplasmsRecurrent Renal Cell CarcinomaMetastatic Renal Cell CarcinomaRefractory Renal Cell CarcinomaAdvanced Renal Cell CarcinomaHypoxiaRenal Cell CarcinomaHypoxia Inducible Factor (HIF)HIF2α InhibitorHypoxia Inducible Factor 2 Alpha (HIF-2 Alpha)Hypoxia Inducible Factor 2α (HIF-2α)Clear Cell

Interventions

DRUG

Oral NKT2152

Oral HIF2α inhibitor

Trial Locations (13)

30322

Emory University, Atlanta

46202

Indiana University Simon Comprehensive Cancer Center, Indianapolis

52242

University of Iowa, Iowa City

68130

Nebraska Cancer Specialists, Omaha

73117

University of Oklahoma, Oklahoma City

77030

MD Anderson Cancer Center, Houston

80218

Sarah Cannon Research Institute, Denver

85258

HonorHealth, Scottsdale

90095

UCLA, Los Angeles

97239

Oregon Health and Science University, Portland

98109

Seattle Cancer Care Alliance, Seattle

20892-9760

National Cancer Institute, Bethesda

02215

Dana Farber Cancer Institute, Boston